Amyloidosis Light-chain

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-24
Clinical Trial Update: Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis [Phase 2]
Phase 2 dose schedule study of Elranatamab for newly diagnosed AL amyloidosis; trial is not yet Recruiting.